.

Iveric bio Inc. traded at $17.94 this Friday September 30th, increasing $0.64 or 3.70 percent since the previous trading session. Looking back, over the last four weeks, Iveric bio Inc. gained 82.32 percent. Over the last 12 months, its price rose by 7.75 percent. Looking ahead, we forecast Iveric bio Inc. to be priced at 14.71 by the end of this quarter and at 13.43 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
17.94
Daily Change
3.70%
Yearly
7.75%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Applied Genetic Technologies 0.27 -0.01 -1.88% -90.44%
Alimera Sciences 5.08 -0.17 -3.24% 21.53%
Bioline Rx 0.93 0.03 3.24% -66.85%
CytrRx Corporation 0.10 0.01 6.11% -82.95%
Insmed 21.54 -0.33 -1.51% -21.33%
Nektar Therapeutics 3.20 0.16 5.26% -82.62%
Novartis 75.53 0.61 0.81% -0.70%
Iveric bio Inc. 17.94 0.64 3.70% 7.75%
Regeneron Pharmaceuticals 688.87 -2.95 -0.43% 20.69%
Roche Holding 323.45 3.20 1.00% -6.31%
Sanofi 78.40 0.56 0.72% -5.10%

Indexes Price Day Year
USND 10576 -161.89 -1.51% -27.40%
US2000 1665 -10.21 -0.61% -25.74%

Iveric bio Inc.
IVERIC bio, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company's therapeutics portfolio consists of Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, a high-temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor. The Company's gene therapy portfolio consists of two product candidates in pre-clinical development, IC-100 and IC-200. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.